Dual Regulator (DIA-39-C20): 60mg

Weight management

Description

Dia-39-c20 (dual regulator) is a 39-amino acid dual incretin agonist belonging to the peptide receptor modulator research series. it simultaneously targets both the glp-1 receptor (glp-1r) and the gip receptor (gipr), producing synergistic — not merely additive — metabolic effects through co-activation of overlapping downstream signaling pathways. the backbone is engineered from a gip-based scaffold with aib substitutions at positions 2 and 13 for dpp-4 resistance, and carries a c20 fatty diacid (eicosanedioyl) side chain via a γ-glu-2x aeea linker for albumin binding and extended once-weekly half-life. cas: 2023788-19-2. structurally analogous in class to tirzepatide. once-weekly subcutaneous injection. key reference literature: coskun et al. (cell metabolism 2022) — ly3437943 triple receptor agonist, discovery to clinical proof; urva et al. (lancet 2022) — phase 1b multiple-ascending dose trial; jastreboff et al. (nejm 2022) — tirzepatide once weekly for the treatment of obesity (surmount-1).

Specifications

Amount in Vial 60mg
BAC Water 3ml
Amount per Unit 0.2mg per unit
Recommended Dose titrate up from 2.5mg to 15mg (12.5 to 75 units)
Frequency 1x per week
Injection Type Subcutaneous
Timing Same Day Every Week / Starting Dose Is 2.5 MG — Titrate Slowly

Dose Calculator

Based on 0.2mg per unit (100-unit insulin syringe)

Quick Reference

Category Weight management
Dose Range titrate up from 2.5mg to 15mg (12.5 to 75 units)
Frequency 1x per week
Route Subcutaneous

Reconstitution

Vial size: 60mg

Add BAC water: 3ml

Concentration: 0.2mg per unit

For research and educational use only.

This page provides research dosing information only. Not intended as medical advice. Consult a qualified professional before any use.